Carvedilol Prevents Redox Inactivation of Cardiomyocyte B₁-Adrenergic Receptors

Misun Park, MD, Susan F. Steinberg, MD

HIGHLIGHTS
- Oxidative stress induced by acute H₂O₂ or chronic doxorubicin treatment leads to a decrease in β₁AR expression and isoproterenol responsiveness in cardiomyocytes.
- The redox-dependent disruption of the β₁AR signaling pathway, which could explain the defect in catecholamine responsiveness that characteristically develops in heart failure, is prevented by the novel protein kinase C inhibitor GFX109203X or carvedilol.
- Carvedilol treatment leads to the accumulation of a truncated β₁AR species whose signaling properties can be distinguished from full-length β₁ARs; truncated β₁ARs constitutively activate protein kinase B and protect against doxorubicin-induced apoptosis.
- These results identify a novel β₁AR-dependent mechanism that contributes to carvedilol-induced cardioprotection.
**ABBREVIATIONS AND ACRONYMS**

| Acronym | Definition |
|---------|------------|
| βARs   | β-adrenergic receptor(s) |
| AKT    | protein kinase B |
| cAMP   | cyclic adenosine monophosphate |
| CREB   | cyclic adenosine monophosphate binding response element protein |
| ERK    | extracellular regulated kinase |
| FL     | full-length |
| GFX    | GF109203X |
| GRK    | G protein-coupled receptor kinase |
| HF     | heart failure |
| PKA    | protein kinase A |
| PKC    | protein kinase C |
| PTX    | pertussis toxin |
| ROS    | reactive oxygen species |

**SUMMARY**

The mechanism that leads to a decrease in β₁-adrenergic receptor (β₁AR) expression in the failing heart remains uncertain. This study shows that cardiomyocyte β₁AR expression and isoproterenol responsiveness decrease in response to oxidative stress. Studies of mechanisms show that the redox-dependent decrease in β₁AR expression is uniquely prevented by carvedilol and not other β₁AR ligands. Carvedilol also promotes the accumulation of N-terminally truncated β₁ARs that confer protection against doxorubicin-induced apoptosis in association with activation of protein kinase B. The redox-induced molecular controls for cardiomyocyte β₁ARs and pharmacologic properties of carvedilol identified in this study have important clinical and therapeutic implications. (J Am Coll Cardiol Basic Trans Sci 2018;3:521–32) © 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Catecholamines enhance the mechanical performance of the heart by activating cardiac β-adrenergic receptors (βARs). Although cardiomyocytes co-express β₁AR and β₂ARs, the β₁AR is the predominant subtype and principal driver of catecholamine-driven sympathetic responses in the healthy heart. β₁ARs couple to a Gₐ-cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) pathway that phosphorylates substrates that enhance excitation/contraction coupling and provide hemodynamic support in the setting of an acute stress. Although β₁ARs also couple to cardioprotective Gₛ-independent mechanisms such as extracellular regulated kinase (ERK) (4), chronic/persistent β₁AR activation leads to a spectrum of changes (including cardiomyocyte hypertrophy/apoptosis, interstitial fibrosis, and contractile dysfunction) that contribute to the pathogenesis of heart failure (HF) (2). βAR inhibitors that prevent maladaptive cAMP-driven βAR responses have become mainstays of HF therapy.

Although βAR activation provides hemodynamic support and compensates for the contractile dysfunction that develops in HF, chronic HF leads to a loss of cardiac reserve due to desensitization and/or down-regulation of βARs (2). Decreased β₁AR density is a hallmark of HF, but the mechanism underlying this adaptive mechanism remains uncertain because the classic paradigms for βAR regulation are based largely on studies of the β₁AR subtype. Current models hold that agonists stabilize βARs in an active conformation that is phosphorylated by G protein-coupled receptor kinases (GRKs). GRK-phosphorylated βARs then recruit β-arrestin, which functions both to initiate desensitization and facilitate clathrin-mediated βAR internalization (3). However, the general assumption that this mechanism applies equally to β₁AR and β₂AR subtypes is at odds with evidence that these receptor subtypes are regulated differently in the setting of HF; HF leads to a relatively selective down-regulation of β₁ARs that is not accompanied by a commensurate loss of β₂ARs (4).

The prevailing assumption that decreased β₁AR expression in the failing heart is attributable to chronic catecholamine-induced, GRK/β-arrestin-dependent receptor desensitization is also at odds with cell-based studies showing that β₁ARs are relatively resistant to agonist-induced, GRK-dependent phosphorylation; they engage β-arrestin only weakly; and they show little-to-no agonist-induced internalization (5,6). These differences should not be surprising because β₁AR and β₂ARs share only 54% overall homology at the amino acid level, with sequence conservation confined largely to transmembrane/ligand-binding regions; β₁AR and β₂AR intracellular loops and C-termini (regions that serve as substrates for GRK phosphorylation and/or docking sites for β-arrestin) are divergent (7). This study identifies an alternative redox-activated mechanism that selectively decreases cardiomyocyte β₁ARs.

In the course of these studies, we also identified a heretofore unrecognized property of carvedilol, a βAR inhibitor that reportedly offers survival advantages over other βAR inhibitors in the treatment of HF (8). Earlier studies have argued that this finding might be attributable to carvedilol’s ancillary properties as an antioxidant (9) or its unique pharmacologic profile; carvedilol acts as an inverse agonist for the βAR- Gₛ- cAMP pathway (i.e., it prevents catecholaminergic-induced cardiotoxicity) and a biased agonist for β-arrestin-mediated signaling to ERK and potentially other cardioprotective pathways (10,11). Our studies show that carvedilol prevents β₁AR redox inactivation and that it also triggers a novel β₁AR-dependent cardioprotective mechanism. We recently found that β₁ARs are detected as both full-length (FL) and
N-terminally truncated species that differ in their signal bias to effector pathways (12). This study shows that carvedilol increases the abundance of N-terminally truncated β1ARs which constitutively activate protein kinase B (AKT) and confer protection against doxorubicin-induced apoptosis.

METHODS

MATERIALS. A full description of the antibodies and chemical reagents can be found in the Supplemental Methods.

CARDIOMYOCYTE CULTURE AND ADENOVIRAL INFECTIONS. Cardiomyocytes were isolated from the ventricles of 2-day-old Wistar rats by a trypsin dispersion technique using a differential attachment procedure to enrich for cardiomyocytes followed by irradiation as described previously (12). Methods to infect cardiomyocytes with adenoviruses that drive expression of FL or N-terminally truncated forms of human β1AR (Ad-FL-β1AR and Ad-Δ2-52-β1AR) were published previously.

IMMUNOBLOTTING. Immunoblotting was performed on cell extracts according to methods described previously (12) or manufacturer’s instructions as detailed in the Supplemental Methods. All results were replicated in at least 3 experiments on separate culture preparations.

MEASUREMENTS OF β1AR DENSITY AND cAMP ACCUMULATION. β1AR density and cAMP accumulation were measured according to standard methods as described previously (12).

STATISTICAL ANALYSIS. Results are shown as mean ± SEM and were analyzed by using Student’s t-test or analysis of variance for multiple comparisons; p values < 0.05 were considered statistically significant.

RESULTS

H2O2 DECREASES β1AR EXPRESSION IN CARDIOMYOCYTES. Reactive oxygen species (ROS) contribute to the pathogenesis of HF and other cardiomyopathic syndromes. Although oxidative stress leads to changes in signaling by many components of the Gs/adenylyl cyclase/PKA pathway, the notion that the β1AR itself is a ROS-sensitive element in this signaling pathway (i.e., that a ROS-dependent event localized to the β1AR itself can contribute to evolution of HF) has never been considered. Our initial studies used immunoblotting to track H2O2-dependent effects on β1AR immunoreactivity.

Because the specificity of various commercially available anti-G protein-coupled receptor antibodies has been questioned (13,14), preliminary studies were designed to rigorously characterize the anti-β1AR antibodies from Abcam and Santa Cruz (SC) that were used for the analysis. Figure 1A (left) shows that the Abcam anti-β1AR antibody detects human β1ARs heterologously overexpressed in rat cardiomyocytes as a major ~69-kDa band and a minor ~55-kDa species. We recently identified a similar immunoreactive profile for this transgene in 2 different model cell lines and showed that the ~69-kDa species corresponds to FL fully glycosylated β1ARs; the ~55-kDa species corresponds to N-terminally truncated glycosylation-defective β1ARs (12). We also showed that N-terminal truncation does not alter β1AR-binding affinity for the antagonist ligand iodocyanopindolol or lead to changes in basal cAMP/PKA or ERK; instead, the N-terminally truncated β1AR is stabilized in a conformation that results in enhanced agonist-dependent activation of cAMP/PKA and reduced agonist-dependent activation of ERK.

The Abcam anti-β1AR antibody does not detect endogenous β1ARs in cardiomyocyte cultures (Figure 1A, left). However, consistent with previous studies showing that the SC anti-β1AR antibody recognizes endogenous mouse β1ARs in lysates from wild-type, but not β1AR knockout, hearts (15,16), Figure 1A (right) shows that the SC anti-β1AR antibody detects a band corresponding to the FL-β1AR in uninfected rat cardiomyocyte cultures and that the abundance of this band increases in the context of β1AR overexpression. The SC anti-β1AR antibody also detects a band with considerably faster electrophoretic mobility. Although this species might represent endogenous N-terminally truncated β1ARs, it could not unambiguously be identified as a bona fide β1AR species because it does not increase with β1AR overexpression. Because this smaller band could represent nonspecific immunoreactivity, it is not considered further in the analysis.

Initial studies used the SC anti-β1AR antibody to track H2O2-dependent regulation of the native β1AR in cardiomyocyte cultures. Figure 1B shows that treatment with 0.1 mM H2O2 leads to a time-dependent decrease in β1AR immunoreactivity. The decrease in overall β1AR immunoreactivity is detected in cultures treated with a range of H2O2 concentrations (0.05 to 5 mM) (Figure 1C). Experiments using low H2O2 concentrations (0.05 to 0.1 mM) also captured a decrease in FL-β1AR electrophoretic mobility (which could suggest an H2O2-dependent increase in β1AR phosphorylation), as well as the accumulation of small amounts of a ~50-kDa species that is presumed to represent a β1AR cleavage product. The H2O2-dependent decrease in β1AR immunoreactivity is specific and is
not accompanied by a change in cardiomyocyte β2ARs (Figure 1D). Importantly, the response to H2O2 contrasts markedly with the response to chronic isoproterenol stimulation (30 to 120 min), which leads to a profound down-regulation of β2ARs and no change in the abundance of the β1AR subtype.

Because β1AR immunoreactivity could in theory be disrupted by an H2O2-dependent post-translational modification at the β1AR C-tail (which harbors the recognition epitopes for both anti-β1AR antibodies), we also performed radioligand binding experiments with 125I-iodocyanopindolol, a high-affinity β1AR antagonist that does not discriminate between β1ARs and β2ARs. Figure 1E shows that this alternative method also identifies an H2O2-dependent decrease in β1AR density.

**THE H2O2-DEPENDENT DECREASE IN β1AR IMMUNOREACTIVITY IS PREVENTED BY GF109203X AND CARVEDILOL.** Cardiomyocytes were challenged with H2O2 in the presence of compounds that inhibit various signaling enzymes implicated as downstream components of the β1AR signaling response as an initial strategy to identify mechanism. Studies were performed in parallel on uninfected cardiomyocytes (to track H2O2-dependent effects on the native rat β1AR) as well as cardiomyocytes that heterologously overexpress human β1ARs. This approach allowed us to screen for possible differences in H2O2-dependent regulation of Gly49 (rodent) versus Ser49 (human) β1AR variants. Immunoblotting studies on overexpressed human β1ARs performed in parallel with Abcam and SC anti-β1AR antibodies also allowed us to further validate the specificity of these reagents. Figure 2A shows that H2O2 treatment leads to similar changes in native and heterologously overexpressed β1AR immunoreactivity. In each case, H2O2 treatment led to an initial decrease in β1AR electrophoretic mobility (best detected at the 30-min time point) followed by a decrease in β1AR immunoreactivity (detected at 60 min). Figure 2A shows that the H2O2-dependent mobility shift (at 30 min) and the
A decrease in βAR immunoreactivity (at 60 min) are both completely abrogated by GF109203X (GFX; a general protein kinase C [PKC] inhibitor) but not by Gö6976 (which selectively blocks calcium-sensitive PKC isoforms or protein kinase D), the PKA inhibitor H-89, or the Src kinase inhibitor PP1. Although there is precedent for a switch in the β1AR’s G protein-coupling specificity from Gs to Gi.

Figure 2: The H2O2-dependent Decrease in β1AR Immunoreactivity Is Prevented by GFX or Carvedilol

(A and C) Cardiomyocytes were pretreated for 1 h with 10 μM GF109203X (GFX), 10 μM PP1, 10 μM H89, 10 μM Gö6976, 0.1 μM propranolol (prop), 1 μM isoproterenol (iso), 1 μM carvedilol (carv), 10 μM pindolol (pin), 10 μM timolol (tim), 10 μM atenolol (aten), or 10 μM metoprolol (met) as indicated and then challenged with vehicle or 0.1 mM H2O2 for 60 min (unless indicated otherwise). (B) Treatment with vehicle or the indicated concentrations H2O2 (in the absence or presence of 1 μM carvedilol) followed a 24-h pre-incubation with 100 ng/ml pertussis toxin (PTX). Experiments in A to C were performed in parallel on cardiomyocyte cultures that did or did not overexpress the β1AR transgene to compare stimulus-induced changes in native rat β1ARs (tracked with SC anti-β1AR antibody) and heterologously overexpressed human β1ARs (tracked with SC and/or Abcam anti-β1AR antibodies as indicated). Because β-actin immunoreactivity was not altered by β1AR overexpression, a single β-actin blot from uninfected cultures is depicted in the figures as a protein loading control. H2O2 and carvedilol-dependent changes in endogenous or heterologously overexpressed β1AR immunoreactivity are quantified in A, right (n = 6). (D) β1AR-overexpressing cardiomyocytes were treated for 24 h with a panel of β1AR ligands (at concentrations stipulated in A). Effects on βAR transgene abundance are depicted on top, with results for 3 separate experiments on different culture preparations quantified on the bottom (*p < 0.05 by analysis of variance followed by a Tukey post hoc analysis). For quantification of immunoreactivity (which is expressed as arbitrary units), levels of the truncated β1AR species in ligand-treated cultures (gray bars) were normalized to the level of the truncated β1AR species in the corresponding vehicle-treated culture (black bar), which was set to 100%. (E) β1AR-overexpressing cardiomyocytes were pretreated for 24 h with vehicle, 1 μM carvedilol, or 5 μM mitoTempo (mitoT, Sigma-Aldrich, St. Louis, Missouri) and then challenged with 100 μM H2O2 as indicated. Lysates were probed for β1AR immunoreactivity with β-actin immunoreactivity included as a loading control. The experiment is representative of data obtained in 4 separate experiments on different culture preparations. (F) Lysates from cardiomyocytes treated for 1 h with vehicle or 100 μM H2O2 (following a 1-h pretreatment with vehicle or 1 μM carvedilol as indicated) were probed for cyclic adenosine monophosphate binding response element-protein (CREB) phosphorylation and CREB protein expression. All immunoblotting data represent results obtained in 3 to 5 separate experiments. Abbreviations as in Figure 1.
under certain stimulatory conditions (17), the observation that the H2O2-dependent decrease in native or heterologously overexpressed β1AR immunoreactivity is preserved in pertussis toxin (PTX)-pretreated cardiomyocytes (Figure 2B) indicates that H2O2-dependent regulation of β1ARs is not through a Gγ-dependent mechanism. Rather, these results indicate that H2O2 regulates endogenous rodent β1ARs and heterologously overexpressed human β1ARs in a similar manner and that H2O2-dependent regulation of β1ARs is via a mechanism that requires a novel PKC isoform activity.

H2O2 treatments were also performed in the presence of various adrenergic receptor ligands to determine whether redox sensitivity is influenced by the activation state or conformation of the β1AR. Figures 2A and 2B show that H2O2-dependent decreases in native and heterologously overexpressed β1ARs are completely abrogated by carvedilol but not by isoproterenol or propranolol. The protective effect of carvedilol is also preserved in PTX-treated cardiomyocytes, and it is specific; various other βAR antagonists (pindolol, timolol, atenolol, and metoprolol) do not share this action (Figure 2C). Studies performed on cardiomyocytes that heterologously overexpressed human β1ARs (where both FL and N-terminally truncated β1AR species could unambiguously be tracked with the Abcam antibody) also exposed an additional effect of carvedilol to increase basal levels of the more rapidly migrating N-terminally truncated β1AR species (Figure 2D). This action is also unique to carvedilol; the abundance of the N-terminally truncated β1AR species is not influenced by other βAR ligands.

These unique actions of carvedilol to protect β1ARs from H2O2-dependent inactivation and increase expression of N-terminally truncated β1AR species are intriguing, given reports that carvedilol might offer survival advantages over other βAR blockers in patients with HF (8). Although some have argued that carvedilol might exert distinct clinical actions by virtue of its unique pharmacologic profile (carvedilol acts as an inverse agonist for the Gα-PKA pathway but a biased agonist for non-G protein/β-arrestin-dependent signaling (11)), carvedilol also possesses antioxidant properties (9). Therefore, it was important to consider whether carvedilol protects β1ARs from H2O2-dependent inactivation by limiting oxidative stress, in essence mimicking the actions of the mitochondrial-targeted antioxidant mitoTEMPO (Sigma-Aldrich, St. Louis, Missouri, which prevents the H2O2-dependent decrease in β1AR (Figure 2E)). The observations that the effect of carvedilol to increase the abundance of the more rapidly migrating N-terminally-truncated β1AR species is not mimicked by mitoT (Figure 2E) and that carvedilol treatment does not block the H2O2-dependent increase cAMP binding response element protein (CREB) phosphorylation at Ser133 (a signaling response that results from the activation of several H2O2-sensitive signaling kinases that cooperate to phosphorylate CREB (18) (Figure 2F)) argue that the β1AR-regulatory actions of carvedilol cannot simply be ascribed to its antioxidant properties.

**DOXORUBICIN DECREASES β1AR LEVELS IN CARDIOMYOCYTES; CARVEDILOL PREVENTS THE DOXORUBICIN-INDUCED DECREASE IN β1ARs.**

Doxorubicin is a chemotherapeutic agent that is highly effective in the treatment of various hematologic and solid tissue malignancies. Although the anticancer effects of doxorubicin derive primarily from its actions to intercalate into nucleic acid side chains and disrupt deoxyribonucleic acid/ribonucleic acid synthesis and repair, doxorubicin treatment also leads to the generation of ROS species that contribute to doxorubicin-induced cardiotoxicity (19). We therefore examined whether doxorubicin treatment influences β1ARs.

Figure 3A shows that doxorubicin treatment leads to a dose-dependent decrease in FL-β1AR immunoreactivity and that this action is associated with the predicted defect in β1AR-signaling responses; isoproterenol-dependent increases in cAMP accumulation and ERK phosphorylation are blunted in doxorubicin-treated cardiomyocytes (Figure 3B). Of note, doxorubicin specifically regulates the β1AR subtype; doxorubicin treatment does not lead to a change in β2AR immunoreactivity (Figure 4A).

The doxorubicin-dependent decrease in β1AR immunoreactivity is prevented by carvedilol (Figure 3A), much like the response to an acute challenge with H2O2. However, chronic 24-h doxorubicin treatment also leads to the accumulation of the smaller ~55-kDa β1AR species. This band, which increases in cardiomyocytes treated with carvedilol alone, becomes prominent in cardiomyocytes treated with doxorubicin in the presence of carvedilol.

**N-TERMINALLY TRUNCATED β1ARs THAT ACCUMULATE IN CARVEDILOL-TREATED CARDIOMYOCYTES CONSTITUTIVELY ACTIVATE AKT AND CONFER PROTECTION AGAINST DOXORUBICIN-INDUCED APOPTOSIS.**

Carvedilol has been characterized as an antagonist for the classic Gα-cAMP pathway and a biased agonist for the GRK/β-arrestin pathway that activates ERK and potentially other cardioprotective pathways (11,20); thus, the carvedilol-rescued β1AR
could in theory confer protection against doxorubicin-induced apoptosis. In fact, Figure 4 shows that doxorubicin treatment leads to the accumulation of a caspase-3 cleavage product and that the level of this apoptosis marker is reduced when doxorubicin treatment is in the presence of carvedilol. Of note, this antiapoptotic action of carvedilol is associated with a modest increase in the phosphorylation of AKT but no detectable increase in ERK phosphorylation.

The failure to identify a carvedilol-dependent increase in ERK phosphorylation was somewhat surprising, given previous evidence that carvedilol acts as a biased agonist for the β-arrestin-ERK pathway (11). However, previous conclusions were based almost exclusively on experiments performed in model cell lines that heterologously overexpress epidermal growth factor receptors; evidence that carvedilol activates ERK in cardiomyocytes is conspicuously absent. In fact, Figure 4B shows that isoproterenol induces a rapid increase in ERK phosphorylation (at 2 to 5 min), whereas carvedilol-activated β1ARs do not increase ERK phosphorylation under these conditions in neonatal rat cardiomyocyte cultures. Rather, carvedilol (much like isoproterenol) activates AKT; this response is detected after more prolonged agonist stimulations (at 30 min).
These results raise the intriguing hypothesis that carvedilol rescues cardiomyocytes from doxorubicin-induced apoptosis by activating a cardioprotective AKT phosphorylation pathway. Two mechanisms are possible. In theory, carvedilol might induce cardioprotection by preventing redox inactivation of FL-$\beta_1$ARs because the carvedilol-rescued FL-$\beta_1$ARs would be stabilized in a conformation that activates AKT. Alternatively, the actions of carvedilol to increase expression of the truncated $\sim$55-kDa $\beta_1$AR species might be cardioprotective, if the N-terminally truncated $\beta_1$AR species displays signaling bias to AKT or other antiapoptotic pathways. The N-terminally truncated $\Delta$2-52-$\beta_1$AR species (designed to mimic the $\beta_1$AR cleavage product that accumulates in carvedilol-treated cardiomyocytes) was heterologously overexpressed in cardiomyocytes to resolve these alternative mechanisms. We previously showed that $\Delta$2-52-$\beta_1$AR overexpression does not result in changes in basal cAMP levels or ERK phosphorylation in cardiomyocytes (12). However, Figure 5A shows that $\Delta$2-52-$\beta_1$AR overexpression leads to the constitutive activation of AKT and reduced doxorubicin-dependent apoptosis (tracked as caspase-3 and poly(ADP-ribose) polymerase cleavage).

The G protein-independent/β-arrestin-dependent pathway that links G protein-coupled receptors to ERK activations can also lead to the activation of AKT; however, a β-arrestin-dependent $\Delta$2-52-$\beta_1$AR-AKT activation pathway seemed unlikely given previous evidence that $\Delta$2-52-$\beta_1$ARs display reduced agonist-dependent activation of ERK (12). Rather, Figure 5B shows that the increase in basal AKT phosphorylation in $\Delta$2-52-$\beta_1$AR overexpressing cardiomyocytes is completely abrogated by PTX, implicating a PTX-sensitive $G_i$ protein in this pathway. Collectively,
these results identify a novel role for N-terminally truncated β1ARs that accumulate in carvedilol-treated cardiomyocytes as activators of a G_i-AKT pathway and mediators of cardioprotection.

**DISCUSSION**

The factors that regulate βAR responsiveness, which provide hemodynamic support in response to stress but also contribute to the pathogenesis of HF, have been the focus of extensive investigation. The published data historically has focused on homologous desensitization mechanisms involving GRKs and β-arrestins that prevent βAR coupling to G proteins, promote βAR internalization, and terminate signaling via the cAMP pathway. However, cell-based studies showing that β1ARs are relatively refractory to this form of desensitization raise questions as to the mechanism underlying the defect in β1AR responsiveness that characteristically develops in HF (5,6). This dilemma is not necessarily resolved by studies that identify alternative mechanisms to influence cardiac catecholamine responsiveness because these mechanisms alter signaling by the β2AR subtype (21–26). Similarly, although there is evidence that doxorubicin treatment leads to a selective decrease in cardiac β1AR expression without an associated decrease in β2ARs (27,28), these previous experiments do not specifically address the underlying mechanism (and the role of oxidative stress) because the changes in β1AR expression occur in the context of a doxorubicin-induced contractile defect that alone would be predicted to impair βAR responsiveness. Studies reported herein provide novel evidence that oxidative stress, a stimulus that contributes to the...
ROS Disrupts $\beta_1$ARs, Carvedilol to the Rescue

In an attempt to identify mechanisms, we found that the H$_2$O$_2$-dependent decrease in $\beta_1$AR expression is abrogated by GFX and carvedilol. The mechanism underlying the protection afforded by GFX remains uncertain. Although the $\beta_1$AR third intracellular loop contains a consensus phosphorylation motif for basophilic kinases (and could in theory serve as a substrate for PKC), phosphorylation at this site has previously been attributed to PKA (and not PKC). However, the $\beta_1$AR extreme C-terminus conforms to a PDZ motif that interacts with synapse-associated protein SAP97 (29), a scaffolding protein that serves a platform to anchor higher order macromolecular complexes involving $\beta_1$ARs and signaling partners such as PKC (30,31). Studies to determine whether this interaction provides a mechanism for PKC regulation of $\beta_1$ARs and to determine the identity of the novel PKC isoform that prevents the H$_2$O$_2$-dependent decrease in $\beta_1$AR levels are ongoing.

The mechanism underlying carvedilol’s ability to protect $\beta_1$ARs from H$_2$O$_2$-dependent inactivation also is not directly addressed by our studies but may be more explainable. Carvedilol contains a bulky aromatic amine substitution that is not present in other adrenergic ligands. Structural studies indicate that this bulky side group makes unique contacts with an extended $\beta_1$AR ligand-binding pocket that includes the redox-sensitive cysteines in extracellular loop 2 (32), the presumptive redox-sensitive molecular determinants on the $\beta_1$AR extracellular surface. It is tempting to speculate that carvedilol prevents H$_2$O$_2$- or doxorubicin-dependent decreases in $\beta_1$ARs by directly shielding these cysteines from redox inactivation, producing a conformational rearrangement of the extracellular surface so as to bury the redox-sensitive disulfide bonds within the receptor structure, or stabilizing the structure of the reduced receptor.

Previous published data showed that lipophilic ligands (e.g., alpenrolol, carvedilol) act as pharmacologic chaperones to increase levels of immature, smaller 47- to 55-kDa forms of the $\beta_1$AR that lack core glycans (and presumably represent N-terminally truncated $\beta_1$ARs), which otherwise are retained in the endoplasmic reticulum and targeted for degradation (33); these could also explain carvedilol’s actions to increase levels of the N-terminally truncated $\beta_1$AR species. Our results suggest that levels of the N-terminally truncated $\beta_1$AR (the minor $\beta_1$AR species in most cardiomyocyte preparations) are limited by endoplasmic reticulum quality control systems that recognize truncated $\beta_1$ARs as improperly or incompletely folded proteins; these findings also suggest that carvedilol stabilizes N-terminally truncated $\beta_1$ARs in a conformation that facilitates their exit from the endoplasmic reticulum and trafficking to their site of action.

Carvedilol abrogates H$_2$O$_2$- and doxorubicin-induced decreases in FL-$\beta_1$AR expression and enhances expression of a cardioprotective N-terminally truncated $\beta_1$AR species; these findings suggest 2 possible mechanisms that could contribute to carvedilol’s antiapoptotic/cardioprotective actions in animal models of ischemia/reperfusion injury and acute myocardial infarction (34) as well as to its actions to protect against doxorubicin-induced cardiotoxicity in the clinic (35-38). First, the carvedilol-rescued FL-$\beta_1$AR would be stabilized in a conformation that activates cardioprotective signaling pathways but not cAMP. Although previous studies in model cell lines showed that carvedilol-activated $\beta_1$ARs stimulate ERK, our studies identified AKT as a downstream effector of carvedilol-activated $\beta_1$ARs in cardiomyocytes. These findings resonate with the recent observation that carvedilol activates a $\beta_1$AR/β-arrestin-dependent pathway that stimulates the processing of certain micro-ribonucleic acids that activate AKT in cardiomyocytes (39). Second, N-terminally truncated $\beta_1$ARs that constitutively activate AKT accumulate in carvedilol-treated cardiomyocytes and would protect against doxorubicin-induced apoptosis. Of note, carvedilol is reported to protect bone marrow stem cells against H$_2$O$_2$-induced cell death, attenuate 6-hydroxydopamine-induced cell death in PC12 cells, and prevent doxorubicin-induced cardiomyopathy, in each case in association with the activation of AKT (40-42). These results suggest that a $\beta_1$AR-AKT pathway plays a more general role in mediating carvedilol’s cytoprotective actions in different cell types.

The observation that the actions of carvedilol to prevent redox inactivation of FL-$\beta_1$ARs and enhance expression of N-terminally truncated $\beta_1$ARs (i.e., promote the accumulation of 2 $\beta_1$AR species that activate a cardioprotective AKT pathway) are not shared by various other $\beta$-blockers also deserves emphasis. Although the notion that $\beta$-blockers provide clinical benefit for patients with HF is not disputed, uncertainties as to whether $\beta$-blockers exert a class effect (i.e., can be used interchangeably in the treatment of patients with HF), or whether carvedilol offers superior clinical efficacy, has never been fully resolved. The incremental survival advantage afforded by carvedilol over metoprolol in COMET...
evidence that carvedilol stabilizes

Lohse MJ, Engelhardt S, Eschenhagen T. What is

transactivation of the EGFR confers car-

Circ Res 2003;93:896

Rockman HA.

Tilley DG, Kim IM, Patel PA, Violin JD,

3.

These studies identify a novel redox-induced mechan-

1ARs; Carvedilol to the Rescue

competency in medical knowledge: A decrease in

β1AR expression and defective catecholamine-dependent re-

responses are hallmarks of HF, but the precise mechanisms that

drive HF-induced changes in β1AR responsiveness remain uncer-
	
because β1ARs are relatively refractory to agonist-

dependent desensitization in cell-based studies. Similarly, βAR inhibitors have become mainstays in the therapy of HF; however,

the factors that contribute to their seemingly counterintuitive cardioprotective actions (whether they act by inhibiting mal-adaptive responses induced by sustained β1AR activation or conversely by resensitizing cardiac βARs and restoring catecholamine responses) remain uncertain. This study expands current β1AR signaling paradigms to show that oxidative stress disrupts β1AR-dependent signaling responses in cardiomyocytes. We also show that certain βAR inhibitors protect βARs from redox inactivation and promote the accumulation of an N-terminally truncated form of the β1AR that displays a unique cardioprotective action.

translational outlook: Current guidelines recommend βAR inhibitors as first-line HF therapy, but controversies as to whether carvedilol (a nonspecific α1, β1, and β2 AR blocker with unique pharmacologic properties) offers survival advantage over other currently available βAR blockers have never been fully resolved. This study identifies novel cardioprotective actions for carvedilol that are not shared by other βAR blockers, showing that carvedilol prevents redox inactivation of the β1AR, and it promotes the accumulation of N-terminally truncated β1ARs that constitutively activate AKT and prevent doxorubicin-induced apoptosis. These unique β1AR-regulatory cardioprotective properties are predicted to offer meaningful survival advantages.

CONCLUSIONS

These studies identify a novel redox-induced mechanism that controls cardiac β1AR responsiveness. The studies also identify a novel β1AR regulatory action for carvedilol, providing a framework to use carvedilol as a prototype for the design of next-generation β1AR-selective compounds with unique β1AR regulatory cardioprotective properties.

REFERENCES

1. Noma T, Lemaire A, Naga Prasad SV, et al. β1-Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers car-

2. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β1-adrenergic signaling in heart failure? Circ Res 2003;93:896-906.

3. Tilley DG, Kim IM, Patel PA, Violin JD, Rockman HA. β-Arrestin mediates β1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem 2009;284:20375-86.

4. Port JD, Bristow MR. Altered β1-adrenergic recep-

tor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 2001;33:887-905.

5. Shina T, Kawasaki A, Naga T, Kurose H. Interaction with β-arrestin determines the difference in internalization behavior between β1- and β2-adrenergic receptors. J Biol Chem 2000;275:29082-90.

6. Green SA, Liggott SB. A proline-rich region of the third intracellular loop imparts phenotypic β1-versus β2-adrenergic receptor coupling and sequestration. J Biol Chem 1994;269:26215-9.

7. Frielle T, Collins S, Daniel KW, Caron MG, LeFkowitz RJ, Kobilka BK. Cloning of the cDNA for the human β1-adrenergic receptor. Proc Natl Acad Sci U S A 1987;84:7920-4.

8. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on...
clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13.
9. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995;16 Suppl F:38–42.
10. Winder JW, DeWire SM, Whalen EJ, et al. A unique mechanism of β-blocker action: carvedilol stimulates β-rearrestin signaling. Proc Natl Acad Sci U S A 2007;104:16657–62.
11. Kim IM, Tilley DG, Chen J, et al. β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A 2008;105:14555–60.
12. Park M, Reddy GR, Wallukat G, Xiang YK, Steinberg SF. β1-adrenergic receptor G-glycosylation regulates N-terminal cleavage and signaling responses in cardiomyocytes. Sci Rep 2017;7:7890.
13. Hamdani N, van der Velden J. Lack of specificity of antibodies directed against human β1-adrenergic receptors. Naunyn Schmiedeberg’s Arch Pharmacol 2009;379:403–7.
14. Kirkpatrick P. Specificity concerns with antibodies for receptor mapping. Nat Rev Drug Disc 2009;8:277.
15. Rybin VO, Xu X, Lisanti MP, Steinberg SF. Differential targeting of β1-adrenergic receptor subtypes and adenyl cyclase to cardiomyocyte caveolae. J Biol Chem 2000;275:41447–57.
16. Rohrer DK, Desai KH, Jasper JR, et al. Targeted disruption of the mouse β1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci U S A 1996;93:7375–80.
17. Martin NP, Whalen EJ, Zamah MA, Pierce KL, Leffkowitz RJ. PKA-mediated phosphorylation of the β1-adrenergic receptor promotes GS/Gi switching. Cell Signal 2004;16:1397–403.
18. Ozgen N, Guo J, Gertsberg Z, Danilo P Jr., Rosen MR, Steinberg SF. Reactive oxygen species decrease cAMP response element binding protein expression in cardiomyocytes via a protein kinase D1-dependent mechanism that does not require Ser231 phosphorylation. Mol Pharmacol 2006;76:896–902.
19. Cappetta D, Rossi F, Piegari E, et al. Doxorubicin targets multiple players: a new view of an old problem. Pharmacol Res 2018;127:4–14.
20. Kim IM, Wang Y, Park KM, et al. β-Arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ Res 2014;114:833–44.
21. Mohan ML, Vaudevan NT, Naga Prasad SV. Proinflammatory cytokines mediate GPCR dysfunction. J Cardiovasc Pharmacol 2017;70:61–73.
22. Prabhud SD. Cytokine-induced modulation of cardiac function. Circ Res 2004;95:1140–53.
23. Vasudevan NT, Mohan ML, Gupta MK, et al. GPCR-independent recruitment of G-protein coupled receptor kinase 2 drives tumor necrosis factor α-induced cardiac β1-adrenergic receptor dysfunction. Circulation 2013;128:377–87.
24. Shi Q, Li M, Mika D, et al. Heterologous desensitization of cardiac β1-adrenergic signal via hormone-induced JAR/arrestin/PDE4 complexes. Cardiovasc Res 2017;113:656–70.
25. Liu S, Li Y, Kim S, et al. Phosphodiesterases coordinate cAMP propagation induced by two stimulatory G protein–coupled receptors in hearts. Proc Natl Acad Sci U S A 2012;109:6578–83.
26. Willoughby D, Baillie GS, Lynch MJ, Ciruela A, Houslay MD, Cooper DM. Dynamic regulation, desensitization, and cross-talk in discrete subcellular microdomains during β1-adrenoceptor and prostanoïd receptor–cAMP signaling. J Biol Chem 2007;282:34235–40.
27. Kenk M, Thackeray JT, Thorn SL, et al. Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity. J Nucl Cardiol 2010;17:254–63.
28. Merlet N, Piriou N, Rozec B, et al. Increased β1-ARs; Carvedilol to the Rescue AUGUST 2018:521–80.
29. Shi Q, Li M, Mika D, et al. Heterologous desensitization of cardiac β1-adrenergic signal via hormone-induced JAR/arrestin/PDE4 complexes. Cardiovasc Res 2017;113:656–70.
30. Liu S, Li Y, Kim S, et al. Phosphodiesterases coordinate cAMP propagation induced by two stimulatory G protein–coupled receptors in hearts. Proc Natl Acad Sci U S A 2012;109:6578–83.
31. Merlet N, Piriou N, Rozec B, et al. Increased β1-adrenoceptor signaling in a rat model of adriamycin-induced cardiotoxicity. J Nucl Cardiol 2010;17:254–63.
32. Merlet N, Piriou N, Rozec B, et al. Increased β1-adrenoceptor signaling in a rat model of adriamycin-induced cardiotoxicity. J Nucl Cardiol 2010;17:254–63.
33. Enright S. Two serines in the distal C-terminus of β1-adrenoceptor initiate of β-arrestin2 recruitment. PloS One 2017;12:e0176450.
34. Yue TL, Ma XL, Gu JL, Ruffolo RR Jr., Feuerstein GZ. Carvedilol inhibits activation of AKT, β1-adrenergic receptor–arrestin biased signaling. Nat Commun 2017;8:1706.
35. Wang L, Wang R, Jin M, et al. Carvedilol attenuates 6-hydroxyporphin-induced cell death in PC12 cells: involvement of Akt and Nr2/AR pathways. Neurochem Res 2014;39:1733–40.
36. Chen YL, Chung SY, Chai HT, et al. Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy. J Pharmacol Exp Ther 2015;355:516–27.
37. Packer M. Do beta-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial. J Card Fail 2003;9:429–43.
38. Wang J, Hanada K, Staus DP, et al. Gn, is required for carvedilol-induced β1-adrenergic receptor–arrestin biased signaling. Nat Commun 2017;8:1706.
39. Hayre M, Eichel K, Avino S, et al. Genetic evidence that β-arrestins are dispensable for the initiation of β1-adrenergic receptor signaling to ERK. Proc Natl Acad Sci USA 2017;114:13395.

KEY WORDS AKT, β1-adrenergic receptor, cardiomyocytes, cardioprotection, oxidant stress

APPENDIX For an expanded Methods section, please see the online version of this paper.